[Heterogeneity of surface antigens in chronic B-cell lymphoid leukemia].
Clinical and immunological studies of fifty patients with CLL have been performed. No correlation was found either between the clinical stage or clinical course of the disease and the distribution of cell surface makers characteristic of CLL (CD19, CD20, CD21, HLA-DR, sIg). Therapy did not influence the distribution of B lymphocyte subpopulations. On the other hand we recognized differences when examining the B-cell specific features. The CD21 antigen was present in significantly lower proportion when compared to all other B-cell markers. This suggests the presence of immature B-cell population. Correlation studies showed a strong correlation between the presence of the CD5 antigen and the antigens CD19, CD20, HLA-DR and sIg, while a similar correlation could not be proved between the CD5 antigen and CD21 marker. Thus the application of the CD5 antibody together with any of the B-cell markers seems to be sufficient for the diagnostics of CLL with the exception of the CD21 antibody that marks only a small proportion of the B-cell population in CLL, so it can be used for purposes of clinical diagnostics.